Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.

Harder BG, Peng S, Sereduk CP, Sodoma AM, Kitange GJ, Loftus JC, Sarkaria JN, Tran NL.

Mol Med. 2019 Nov 14;25(1):49. doi: 10.1186/s10020-019-0116-z.

2.

Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma.

Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, Loftus JC, Tran NL.

Front Oncol. 2018 Oct 23;8:462. doi: 10.3389/fonc.2018.00462. eCollection 2018. Review.

3.

PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival.

Ding Z, Dhruv H, Kwiatkowska-Piwowarczyk A, Ruggieri R, Kloss J, Symons M, Pirrotte P, Eschbacher JM, Tran NL, Loftus JC.

Neoplasia. 2018 Oct;20(10):1045-1058. doi: 10.1016/j.neo.2018.08.008. Epub 2018 Sep 13.

4.

EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC, Winkles JA, Tran NL.

Mol Cancer Res. 2018 Jul;16(7):1185-1195. doi: 10.1158/1541-7786.MCR-18-0125. Epub 2018 May 3.

5.

A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.

Ding Z, Roos A, Kloss J, Dhruv H, Peng S, Pirrotte P, Eschbacher JM, Tran NL, Loftus JC.

Mol Cancer Res. 2018 Feb;16(2):322-332. doi: 10.1158/1541-7786.MCR-17-0454. Epub 2017 Nov 8.

6.

Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion.

Roos A, Ding Z, Loftus JC, Tran NL.

Front Oncol. 2017 Jun 16;7:120. doi: 10.3389/fonc.2017.00120. eCollection 2017. Review.

7.

Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL.

Oncotarget. 2017 Feb 14;8(7):12234-12246. doi: 10.18632/oncotarget.14685.

8.

Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.

Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O'Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR.

Neuro Oncol. 2017 Jan;19(1):128-137. doi: 10.1093/neuonc/now135. Epub 2016 Aug 8.

9.

How Honey Bee Colonies Survive in the Wild: Testing the Importance of Small Nests and Frequent Swarming.

Loftus JC, Smith ML, Seeley TD.

PLoS One. 2016 Mar 11;11(3):e0150362. doi: 10.1371/journal.pone.0150362. eCollection 2016.

10.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

11.

Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.

Dhruv HD, Roos A, Tomboc PJ, Tuncali S, Chavez A, Mathews I, Berens ME, Loftus JC, Tran NL.

J Neurooncol. 2016 Feb;126(3):397-404. doi: 10.1007/s11060-015-1981-0. Epub 2015 Nov 12.

12.

A critical number of workers in a honeybee colony triggers investment in reproduction.

Smith ML, Ostwald MM, Loftus JC, Seeley TD.

Naturwissenschaften. 2014 Oct;101(10):783-90. doi: 10.1007/s00114-014-1215-x. Epub 2014 Aug 21.

PMID:
25142633
13.

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S.

Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196.

14.

Differential expression of microRNAs as predictors of glioblastoma phenotypes.

Bradley BS, Loftus JC, Mielke CJ, Dinu V.

BMC Bioinformatics. 2014 Jan 18;15:21. doi: 10.1186/1471-2105-15-21.

15.

A Novel Interaction between Pyk2 and MAP4K4 Is Integrated with Glioma Cell Migration.

Loftus JC, Yang Z, Kloss J, Dhruv H, Tran NL, Riggs DL.

J Signal Transduct. 2013;2013:956580. doi: 10.1155/2013/956580. Epub 2013 Sep 15.

16.

Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.

Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, Berens ME, Tran NL, Meurice N.

J Biol Chem. 2013 Nov 8;288(45):32261-76. doi: 10.1074/jbc.M113.493536. Epub 2013 Sep 20.

17.

Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.

Dhruv HD, McDonough Winslow WS, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Loftus JC, Tran NL, Berens ME.

PLoS One. 2013 Aug 15;8(8):e72134. doi: 10.1371/journal.pone.0072134. eCollection 2013.

19.

TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.

Loftus JC, Dhruv H, Tuncali S, Kloss J, Yang Z, Schumacher CA, Cao B, Williams BO, Eschbacher JM, Ross JT, Tran NL.

Mol Cancer Res. 2013 Aug;11(8):865-74. doi: 10.1158/1541-7786.MCR-13-0008. Epub 2013 May 22.

20.

New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer.

Whitsett TG, Loftus JC, Winkles JA, Tran NL.

Transl Lung Cancer Res. 2013 Feb;2(1):3-5. doi: 10.3978/j.issn.2218-6751.2012.10.05. No abstract available.

21.

miRNA expression profiling in migrating glioblastoma cells: regulation of cell migration and invasion by miR-23b via targeting of Pyk2.

Loftus JC, Ross JT, Paquette KM, Paulino VM, Nasser S, Yang Z, Kloss J, Kim S, Berens ME, Tran NL.

PLoS One. 2012;7(6):e39818. doi: 10.1371/journal.pone.0039818. Epub 2012 Jun 22.

22.

Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, Tran NL, Winkles JA.

Am J Pathol. 2012 Jul;181(1):111-20. doi: 10.1016/j.ajpath.2012.03.026. Epub 2012 May 23. Erratum in: Am J Pathol. 2012 Nov;181(5):1889.

23.

Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells.

Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, Ross JT, Winkles JA, Loftus JC, Symons MH, Tran NL.

Mol Cancer Res. 2012 Jul;10(7):958-68. doi: 10.1158/1541-7786.MCR-11-0616. Epub 2012 May 9.

24.

TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling.

Paulino VM, Yang Z, Kloss J, Ennis MJ, Armstrong BA, Loftus JC, Tran NL.

Mol Cancer Res. 2010 Nov;8(11):1558-67. doi: 10.1158/1541-7786.MCR-10-0334. Epub 2010 Sep 29.

25.

The Pyk2 FERM regulates Pyk2 complex formation and phosphorylation.

Riggs D, Yang Z, Kloss J, Loftus JC.

Cell Signal. 2011 Jan;23(1):288-96. doi: 10.1016/j.cellsig.2010.09.015. Epub 2010 Sep 16.

26.

Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2.

Meurice N, Wang L, Lipinski CA, Yang Z, Hulme C, Loftus JC.

J Med Chem. 2010 Jan 28;53(2):669-77. doi: 10.1021/jm901247a.

27.

Targeting Pyk2 for therapeutic intervention.

Lipinski CA, Loftus JC.

Expert Opin Ther Targets. 2010 Jan;14(1):95-108. doi: 10.1517/14728220903473194. Review.

28.

Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function.

Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, Loftus JC, Kingsley C, Hostetter G, Tran NL.

Mol Cancer Res. 2009 Nov;7(11):1871-81. doi: 10.1158/1541-7786.MCR-09-0194. Epub 2009 Oct 27.

29.

The Pyk2 FERM domain as a target to inhibit glioma migration.

Loftus JC, Yang Z, Tran NL, Kloss J, Viso C, Berens ME, Lipinski CA.

Mol Cancer Ther. 2009 Jun;8(6):1505-14. doi: 10.1158/1535-7163.MCT-08-1055. Epub 2009 Jun 9.

30.

Differential effects of Pyk2 and FAK on the hypertrophic response of cardiac myocytes.

Menashi EB, Loftus JC.

Cell Tissue Res. 2009 Aug;337(2):243-55. doi: 10.1007/s00441-009-0807-9. Epub 2009 May 12.

31.

Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts.

Lipinski CA, Tran NL, Viso C, Kloss J, Yang Z, Berens ME, Loftus JC.

J Neurooncol. 2008 Nov;90(2):181-9. doi: 10.1007/s11060-008-9656-8. Epub 2008 Jul 22.

32.

Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome.

Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, Nakada M, Cunliffe HE, Hostetter G, Hoelzinger DB, Rennert JL, Michaelson JS, Burkly LC, Lipinski CA, Loftus JC, Mariani L, Berens ME.

Cancer Res. 2006 Oct 1;66(19):9535-42.

33.

Critical role of the FERM domain in Pyk2 stimulated glioma cell migration.

Lipinski CA, Tran NL, Dooley A, Pang YP, Rohl C, Kloss J, Yang Z, McDonough W, Craig D, Berens ME, Loftus JC.

Biochem Biophys Res Commun. 2006 Oct 27;349(3):939-47. Epub 2006 Aug 31.

PMID:
16962067
34.

The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME, Loftus JC.

Neoplasia. 2005 May;7(5):435-45.

35.

Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.

Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ.

Cancer Res. 2005 Jun 15;65(12):5292-300.

36.

Effects of raloxifene hydrochloride on endometrial cancer cells in vitro.

Hibner M, Magrina JF, Lefler SR, Cornella JL, Pizarro AR, Loftus JC.

Gynecol Oncol. 2004 Jun;93(3):642-6.

PMID:
15196858
37.
38.

Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation.

Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME, Loftus JC.

Mol Cancer Res. 2003 Mar;1(5):323-32.

39.

A lethal perinatal cardiac phenotype resulting from altered integrin function in cardiomyocytes.

Valencik ML, Keller RS, Loftus JC, McDonald JA.

J Card Fail. 2002 Aug;8(4):262-72.

PMID:
12397575
40.

Many alphaIIbbeta3 autoepitopes in chronic immune thrombocytopenic purpura are localized to alphaIIb between amino acids L1 and Q459.

McMillan R, Wang L, Lopez-Dee J, Jiu S, Loftus JC.

Br J Haematol. 2002 Sep;118(4):1132-6.

PMID:
12199797
41.

In vitro selection of fibronectin gain-of-function mutations.

Tani PH, Loftus JC, Bowditch RD.

Biochem J. 2002 Jul 1;365(Pt 1):287-94.

42.

Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure.

Shai SY, Harpf AE, Babbitt CJ, Jordan MC, Fishbein MC, Chen J, Omura M, Leil TA, Becker KD, Jiang M, Smith DJ, Cherry SR, Loftus JC, Ross RS.

Circ Res. 2002 Mar 8;90(4):458-64.

PMID:
11884376
43.
44.
45.

Disruption of integrin function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance.

Keller RS, Shai SY, Babbitt CJ, Pham CG, Solaro RJ, Valencik ML, Loftus JC, Ross RS.

Am J Pathol. 2001 Mar;158(3):1079-90.

46.

Striated muscle-specific beta(1D)-integrin and FAK are involved in cardiac myocyte hypertrophic response pathway.

Pham CG, Harpf AE, Keller RS, Vu HT, Shai SY, Loftus JC, Ross RS.

Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2916-26.

47.
48.
49.

Beta1 integrins participate in the hypertrophic response of rat ventricular myocytes.

Ross RS, Pham C, Shai SY, Goldhaber JI, Fenczik C, Glembotski CC, Ginsberg MH, Loftus JC.

Circ Res. 1998 Jun 15;82(11):1160-72.

PMID:
9633916
50.

New insights into integrin-ligand interaction.

Loftus JC, Liddington RC.

J Clin Invest. 1997 Dec 1;100(11 Suppl):S77-81. Review. No abstract available.

PMID:
9413406

Supplemental Content

Loading ...
Support Center